TCIRG1
TCIRG1 (T-cell immune regulator 1) is a gene that encodes a component of the vacuolar ATPase (V-ATPase) complex, which is essential for acidification of intracellular compartments in eukaryotic cells. This acidification is crucial for various cellular processes, including protein sorting, zymogen activation, and receptor-mediated endocytosis.
Function[edit | edit source]
The TCIRG1 gene encodes the a3 subunit of the V-ATPase, which is a multi-subunit enzyme responsible for acidifying a variety of intracellular compartments in eukaryotic cells. The V-ATPase is a proton pump that uses the energy derived from ATP hydrolysis to transport protons across cellular membranes, thereby acidifying the lumen of organelles such as lysosomes, endosomes, and the Golgi apparatus.
The a3 subunit, encoded by TCIRG1, is specifically involved in the acidification of the osteoclast resorption lacuna, a critical process in bone resorption. Osteoclasts are specialized cells that break down bone tissue, and the acidification of the resorption lacuna is necessary for dissolving the mineral component of bone.
Clinical Significance[edit | edit source]
Mutations in the TCIRG1 gene are associated with autosomal recessive osteopetrosis (ARO), a rare genetic disorder characterized by increased bone density and abnormal bone growth due to defective osteoclast function. Patients with ARO often present with symptoms such as bone fragility, cranial nerve compression, and hematological abnormalities due to the failure of bone marrow cavity formation.
The most common mutations in TCIRG1 that lead to osteopetrosis result in a loss of function of the a3 subunit, impairing the ability of osteoclasts to acidify the resorption lacuna and resorb bone effectively.
Research and Therapeutic Approaches[edit | edit source]
Research into TCIRG1 and its role in osteoclast function has provided insights into potential therapeutic approaches for treating osteopetrosis. Gene therapy, bone marrow transplantation, and pharmacological agents that can compensate for the defective acidification process are areas of active investigation.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD